Innovation Takes All of Us

Niels Emmerich, Vice President, Global Head Search & Evaluation and Global Alliances
Li Liu, Senior Director, Oncology
Rohun Palekar, Director, Specialty
Arpita Maiti, Vice President, Immunology, Specialty, EyeCare and Discovery Platforms
Wendy Peters, Senior Director, Immunology
Douglas Faunce, Executive Director, Eye Care
Chinmay Kanuga, Senior Director, Allergan Aesthetics and Operations
Joachim Vogt, Director, Western Europe and Israel
Sergio Capancioni, Director, UK, Ireland, Nordics & Canada
Wendy Tai, Director, Japan/Asia/Pacific
Dong Chen, Executive Director, China
Jess Joseph, Director, Chief of Staff

Garrett Rhyasen, Vice President, Business Development & Acquisitions
Rachel Strick, Vice President, Immunology, Specialty, Eye Care and Discovery Platforms
Rahul Jerath, Senior Director, Oncology
Tony Brazda, Senior Director, Neuroscience
David Moss, Associate VP, Eye Care
Sridhar Mandapati, Senior Director, International Business Development
Siddharth Kishore, Director, Chief of Staff

Jonathan Kern, Vice President, Global Alliances
Jason Powell, Senior Director, Enterprise Partnerships
Shankar Subramanian, Senior Director, Specialty & Academic Partnerships
Sebastian Espinosa, Senior Director, Oncology
Jeremy Schieler, Director, Oncology
Danielle Reitsma, Director, Oncology
Rajiv Janjikhel, Senior Director, Neuroscience, Eye Care
Allison Hoch, Director, Neuroscience, Eye Care, Immunology
Melanie Patterson, Director, Neuroscience
Amanda McAllister, Director, Discovery Platforms, Allergan Aesthetics, Neurotoxins
Sherket Peterson, Director, Aesthetics
Cardine Nokwe, Director, Immunology, Specialty
Sarah E Lidtke, Director, Immunology
Jun Li, Director, Oncology

Christian Schubert, Vice President and Head, Boston / Cambridge area
Doug Faunce, Executive Director, Irvine area
Shawna Frazier, Director, San Francisco area
Donmienne Leung, Director, Oxford area
Claire Leurent, Senior Director, Cambridge area
Joachim Vogt, Director, Ludwigshafen area
Christina Vorvis, Director, Boston / Cambridge area
Tom Wu, Scientist-in-Residence, Shanghai, China area
Shann Yu, Associate Director & Chief of Staff, Boston / Cambridge area
Laura Pedroza, AD, Ludwigshafen area
Simranjit Singh, AD, San Francisco area
Keith Hamel, Scientist-in-Residence, Chicago area
Jeremy Edmunds, Senior Venture Partner, Worcester area
Michael Rosenzweig, Senior Venture Partner, Boston area
Albert Lai, Senior Venture Partner, San Francisco area

As a leading expert in autoimmune diseases and therapies, AbbVie is focused on developing new medicines to address chronic progressive diseases within immunology. Our goal is to identify therapeutic approaches that have the potential to transform the lives of people with immune-mediated diseases. 

Our areas of interest include:

• Gastroenterology (Crohn's disease, ulcerative colitis)
• Dermatology (psoriasis, atopic dermatitis, hidradenitis suppurativa)
• Rheumatology (rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis/nr-AxSpA)
• Respiratory (asthma, COPD, IPF)
• Th2-mediated diseases (eosinophilic diseases, chronic urticarias)
• Select B cell mediated diseases (SLE, systemic sclerosis, Sjogren’s syndrome)
• Select fibrotic conditions (systemic sclerosis, IPF)

Our therapeutic modalities focus on targeting potent drugs to the right cells and/or tissues.  These include bispecific/multi-specific biologics, Antibody-Drug Conjugates, small molecules, oral peptides, and genetic medicines (RNA therapeutics and in situ cell reprogramming). 

Our goal is to discover and develop breakthrough therapies that benefit patients with hematologic and solid tumor malignancies, especially those with unmet need. We are committed to achieving long-term control and potential cure, using oral small molecules, targeted biologics (including mAb, bispecific, ADCs) or novel modality therapeutics.

Our areas of interest include:

• Novel or differentiated programs in these core tumor types
• Lung cancer (NSCLC, SCLC)
• GI cancer (CRC, PDAC)
• Ovarian and other gynecological cancer
• Multiple myeloma
• B cell malignancy (NHL and CLL)

We are dedicated to delivering science that brings us closer to making a significant impact for people living with neurological and psychiatric disorders. AbbVie’s neuroscience portfolio comprises approved therapies and a robust pipeline to address some of the most serious and prevalent disorders in this space.

Our areas of interest include:

• Psychiatric diseases including mood, stress/anxiety, and psychosis-related disorders
• Parkinson’s disease including symptomatic (motor & non-motor) and disease modification approaches; other movement related disorders (e.g. tremor, spasticity, dyskinesia etc.)
• Migraine and related disorders
• Alzheimer’s disease, including symptomatic (cognitive, neurobehavioral) and disease modification approaches; other neurodegenerative diseases, especially those driven by shared biological pathways.

Our mission remains to protect and preserve vision for a better quality of life for the millions of people who experience vision loss every year. AbbVie continues to search for new therapeutics and approaches that address unmet needs in retina-related diseases, glaucoma and other conditions. We are largely focused on biologics and small molecules, as well as next-generation drug delivery technologies.

Our areas of interest include:

• Retinal degeneration, including dry AMD/geographic atrophy, wet AMD, and diabetic retinal diseases
• Dry eye and ocular surface disease, including novel artificial tears
• Glaucoma, addressing sustained drug delivery and neuroprotection

Allergan Aesthetics offers a portfolio of innovative products in facial and body filling, breast reconstruction/augmentation, and regenerative soft tissue repair. We are interested in strategic partnerships that broaden our understanding of the aging process and therapeutic targets to address physical and biological changes that occur with age. Our focus is on neurotoxins, dermal fillers, body aesthetics, and other treatments as well as energy-based devices within aesthetics and cell and gene therapies concentrating on extracellular matrix components, including collagen and elastin.

Our areas of interest include:

• Dermal injectables for skin and tissue
• Plastics and regenerative medicine
• Toxins for aesthetic and therapeutics
• Hair growth
• Body contouring and fat reduction
• Topical skincare
• Therapies that improve body composition

Our specialty team focuses on a diverse set of diseases with high unmet needs, where we believe great progress for patients is possible. In addition to supporting various on-market products, we are interested in strategic partnerships to grow our presence in obesity, aiming to identify differentiated opportunities for addressing patient needs in weight management.

Our areas of interest include:

• Obesity
• GI/hepatology (e.g. MASH)

We strive to leverage a diverse range of next-generation platforms and comprehensive technologies to enable novel methods for target identification and drug discovery.

Our areas of interest include:

• Novel approaches and platform technologies that enable the discovery of small molecules targeting protein classes traditionally considered undruggable
• New and emerging small molecule therapeutic modalities, including, but not limited to, targeted protein degradation, other proximity-inducing bifunctional molecules and RNA targeting
• Biotherapeutics, particularly multi-specific antibodies and antibody-drug conjugates
• Genetic medicine platforms, including viral and non-viral delivery of DNA/RNA and in vivo chimeric antigen receptor T-cell (CAR-T)
• Genetics and genomics, including multi-omic approaches and technologies
• Artificial intelligence (AI) and machine learning (ML) driven target identification and prioritization and AI/ML/physics-based computational design and optimization of small molecules and biotherapeutics